Jeremy Tan, MD
Psychiatry · Hutchinson, KSNPI 1245256023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,107 and has fallen 71.4% since, to $317 in 2025.
Across 265 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$808
- Vanda Pharmaceuticals Inc.$551
- Johnson & Johnson$352
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$351
- Teva Pharmaceuticals USA, Inc.$306
- Alkermes, Inc.$297
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,11499%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $808 |
| Vanda Pharmaceuticals Inc. | 20 | $551 |
| Johnson & Johnson | 18 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $351 |
| Teva Pharmaceuticals USA, Inc. | 17 | $306 |
| Alkermes, Inc. | 15 | $297 |
| Supernus Pharmaceuticals, Inc. | 17 | $266 |
| Neurocrine Biosciences, Inc. | 11 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $198 |
| Otsuka America Pharmaceutical, Inc. | 11 | $195 |
| Indivior Inc. | 7 | $111 |
| Lundbeck LLC | 5 | $100 |
| Sunovion Pharmaceuticals Inc. | 9 | $93 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Eisai Inc. | 2 | $43 |
| Biogen | 2 | $42 |
| Shire North American Group Inc | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Corium, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$108
How this compares
$4,164 in reported general payments places this provider in the 80th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 44 | $143,532 |
| AristadaAripiprazole Lauroxil | 32 | $86,520 |
| Austedo XrDeutetrabenazine | 11 | $83,958 |
| RexultiBrexpiprazole | 34 | $47,775 |
| Abilify MaintenaAripiprazole | 14 | $40,758 |
| VraylarCariprazine Hcl | 12 | $17,683 |
| Clozapine OdtClozapine | 34 | $15,864 |
| Risperdal ConstaRisperidone Microspheres | 25 | $15,775 |
| FetzimaLevomilnacipran Hcl | 26 | $12,818 |
| Aripiprazole | 250 | $12,700 |
| Paliperidone ErPaliperidone | 51 | $11,887 |
| Lurasidone Hcl | 41 | $8,327 |
| Clozapine | 125 | $7,731 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,702 |
| BelsomraSuvorexant | 13 | $5,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $352 | $159,30769 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $195 | $88,53248 claims |
| Alkermes, Inc.Aristada | $297 | $86,52032 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $306 | $83,95811 claims |
| AbbVieVraylar, Fetzima | $808 | $30,50138 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $198 | $7,70214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Hutchinson
- Veronica Amey PerrinHutchinson$2K
- David WichmanManhattan$613K
- Kevin MaysLeawood$548K
- Sheldon PreskornWichita$498K
- James OwensSalina$433K
- Sasha HamdaniOverland Park$104K
- Christine GlennKansas City$58K
- Heidi OgdenWichita$55K
- Mark RomereimHays$41K
- Patrick StangGreat Bend$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.